The management of chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis B virus (HBV) infection poses significant health risks, necessitating effective therapeutic strategies.
• Current HBV treatment aims to halt disease progression and reduce viral transmission.

Purpose of the Study:

• To evaluate the efficacy of interferon therapy in managing hepatitis B virus infection.
• To identify optimal patient candidates and treatment modifications for improved interferon response rates.

Main Methods:

• Analysis of patient data to assess outcomes of interferon therapy for HBV.
• Identification of baseline characteristics, including aminotransferase and HBV DNA levels, associated with treatment response.
• Investigation of adjunctive therapies, such as prednisone, to enhance response rates in specific patient subgroups.

Main Results:

• Interferon is the most consistently effective treatment for suppressing HBV histologic progression and infectivity.
• Patients with high baseline aminotransferase and low HBV DNA levels show the best response to interferon.
• An alanine aminotransferase (ALT) flare during therapy indicates immunologic activation and predicts a positive response.
• Low baseline ALT levels (<100 U/liter) are linked to lower response rates, but can be improved with short-term prednisone priming.
• While HBV DNA and hepatitis B e antigen loss is generally sustained, approximately 10% of patients experience relapse.

Conclusions:

• Interferon therapy is a valuable tool in managing hepatitis B virus infection, offering sustained viral suppression and improved liver histology.
• Patient selection based on baseline biochemical and virologic markers is crucial for optimizing interferon treatment success.
• Further research is warranted to explore interferon's role in diverse patient populations and refine treatment protocols.